GSS Gene (Glutathione Synthetase)

title: GSS Gene

GSS — Glutathione Synthetase

<div class="infobox infobox-gene">
<div class="infobox-header">GSS</div>
<div class="infobox-row"><span>Full Name:</span> Glutathione Synthetase</div>
<div class="infobox-row"><span>Gene Symbol:</span> GSS</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 20q11.22</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> 2937</div>
<div class="infobox-row"><span>OMIM ID:</span> 601002</div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000100977</div>
<div class="infobox-row"><span>UniProt ID:</span> P16455</div>
<div class="infobox-row"><span>Protein Length:</span> 574 amino acids</div>
<div class="infobox-row"><span>EC Number:</span> 6.3.2.3</div>
</div>

Introduction

GSS (Glutathione Synthetase) is a critical housekeeping gene encoding the second enzyme in the glutathione biosynthesis pathway. Glutathione synthetase catalyzes the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione (GSH), the most abundant cellular antioxidant[@gss2015b]. This enzyme is essential for maintaining cellular redox homeostasis, and its dysfunction has been implicated in numerous neurodegenerative diseases including [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@glutathione2015].

title: GSS Gene

GSS — Glutathione Synthetase

<div class="infobox infobox-gene">
<div class="infobox-header">GSS</div>
<div class="infobox-row"><span>Full Name:</span> Glutathione Synthetase</div>
<div class="infobox-row"><span>Gene Symbol:</span> GSS</div>
<div class="infobox-row"><span>Chromosomal Location:</span> 20q11.22</div>
<div class="infobox-row"><span>NCBI Gene ID:</span> 2937</div>
<div class="infobox-row"><span>OMIM ID:</span> 601002</div>
<div class="infobox-row"><span>Ensembl ID:</span> ENSG00000100977</div>
<div class="infobox-row"><span>UniProt ID:</span> P16455</div>
<div class="infobox-row"><span>Protein Length:</span> 574 amino acids</div>
<div class="infobox-row"><span>EC Number:</span> 6.3.2.3</div>
</div>

Introduction

GSS (Glutathione Synthetase) is a critical housekeeping gene encoding the second enzyme in the glutathione biosynthesis pathway. Glutathione synthetase catalyzes the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione (GSH), the most abundant cellular antioxidant[@gss2015b]. This enzyme is essential for maintaining cellular redox homeostasis, and its dysfunction has been implicated in numerous neurodegenerative diseases including [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@glutathione2015].

GSS is ubiquitously expressed in all tissues, with particularly high levels in the liver, kidney, and brain. The enzyme operates in the cytosol and mitochondria, reflecting the dual importance of glutathione in both cellular compartments. In the [central nervous system](/brain-regions/overview), GSS plays a crucial role in protecting [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes) from oxidative damage that accumulates during normal metabolism and pathological processes[@gss2022].

Molecular Biology

Gene Structure

The GSS gene spans approximately 22 kb on chromosome 20q11.22 and consists of 14 exons. The encoded protein is 574 amino acids long with a molecular weight of approximately 64 kDa. The gene produces multiple transcript variants through alternative splicing, though the functional significance of these variants remains under investigation.

Protein Structure

Glutathione synthetase is a homodimeric enzyme, with each subunit containing:

• N-terminal domain: Binding site for γ-glutamylcysteine
• C-terminal domain: Binding site for glycine and ATP
• Active site: Catalytic residues including Asp487, Lys329, and Glu432

Catalytic Mechanism

The reaction catalyzed by GSS proceeds through a two-step mechanism:

This reaction is highly exergonic (ΔG°' = -50 kJ/mol) and essentially irreversible under physiological conditions.

Function

Glutathione Biosynthesis

GSS is the second and final enzyme in the glutathione biosynthesis pathway:

γ-glutamylcysteine + glycine + ATP → Glutathione (GSH) + ADP + Pi

The pathway begins with glutamate-cysteine ligase (GCLC), which combines glutamate and cysteine to form γ-glutamylcysteine. GSS then adds glycine to complete the tripeptide structure.

Antioxidant Defense

Glutathione serves multiple critical antioxidant functions:

• Direct antioxidant: GSH directly scavenges reactive oxygen species (ROS) and electrophiles
• Detoxification: GSH conjugates to xenobiotics via glutathione S-transferases
• Redox buffer: The GSH/GSSG ratio maintains cellular redox potential
• Protein maintenance: GSH prevents protein thiol oxidation and misfolding

Mitochondrial Function

GSS is essential for mitochondrial health:

• Mitochondrial GSH (mtGSH) constitutes ~10-15% of total cellular GSH
• mtGSH is critical for protecting electron transport chain components
• Loss of mtGSH leads to mitochondrial dysfunction and apoptosis[gss2020]

Neuroprotection

In the nervous system, GSS:

• Protects neurons from oxidative stress-induced death
• Supports astrocyte function and glutamate metabolism
• Maintains blood-brain barrier integrity
• Modulates neuroinflammation through redox signaling

Redox Signaling

Beyond direct antioxidant activity, GSH/GSSG ratios regulate:

• Transcription factor activation (NF-κB, AP-1)
• Protein kinase signaling pathways
• Epigenetic modifications via histone oxidation
• Calcium homeostasis

Disease Associations

5-Oxoprolinuria (Glutathione Synthetase Deficiency)

GSS mutations cause hereditary glutathione synthetase deficiency, manifesting as:

| Clinical Feature | Description |
|-----------------|-------------|
| 5-oxoprolinuria | Elevated urinary 5-oxoproline |
| Metabolic acidosis | Accumulation of acidic metabolites |
| Hemolytic anemia | Red cell fragility |
| Neurological symptoms | Developmental delay, ataxia |
| Seizures | Hyperexcitability |
| Ichthyosis | Skin abnormalities |

Over 30 pathogenic GSS variants have been identified, including missense, nonsense, and splice-site mutations[gss2003].

Alzheimer's Disease

GSS dysfunction contributes to AD pathogenesis through:

• Oxidative stress: Reduced GSH leads to accumulated ROS in [neurons](/entities/neurons)
• Amyloid interaction: GSH modulates amyloid-β aggregation
• Tau pathology: Oxidative stress promotes tau hyperphosphorylation
• Synaptic failure: Redox imbalance impairs synaptic plasticity

Parkinson's Disease

GSS is particularly relevant to PD:

• SNc vulnerability: Dopaminergic neurons have inherently low GSH
• Mitochondrial dysfunction: GSS deficiency exacerbates complex I damage[hj2021]
• α-synuclein: Oxidative stress accelerates α-synuclein aggregation
• Levodopa metabolism: GSH is depleted by levodopa treatment

Amyotrophic Lateral Sclerosis

GSS alterations in ALS:

• Reduced GSH in motor neurons and spinal cord[gss2017]
• Impaired antioxidant response to excitotoxicity
• Association with sporadic ALS cases
• Potential therapeutic target

Autism Spectrum Disorder

GSS variants have been associated with ASD[gss2016]:

• Altered redox homeostasis in affected individuals
• Reduced GSH/GSSG ratio in plasma
• Interaction with environmental risk factors

Cancer

While GSS is generally protective, dysregulation has been noted:

• Overexpression in certain tumors (resistance to chemotherapy)
• GSH-dependent drug efflux pumps
• Prognostic marker in some malignancies

Expression

Tissue Distribution

GSS is expressed ubiquitously:

| Tissue | Expression Level |
|--------|------------------|
| Liver | Highest |
| Kidney | High |
| Brain | Moderate-high |
| Lung | Moderate |
| Heart | Moderate |
| Skeletal muscle | Lower |

Brain Expression

In the central nervous system, GSS is expressed in:

• Neurons: All neuronal populations, particularly [pyramidal cells](/brain-regions/cortex)
• Astrocytes: High expression in Bergman glia and protoplasmic astrocytes
• Oligodendrocytes: Lower expression
• Microglia: Inducible expression during inflammation

• [Cerebral cortex](/brain-regions/cortex) — high
• [Hippocampus](/brain-regions/hippocampus) — high (CA1-CA3, dentate gyrus)
• [Substantia nigra](/brain-regions/substantia-nigra) — moderate
• [Cerebellum](/brain-regions/cerebellum) — moderate

Regulation

GSS expression is regulated by:

• Nrf2 transcription factor: Antioxidant response elements (ARE) in promoter
• NF-κB: Repression under inflammatory conditions
• AP-1: Induction by oxidative stress
• Epigenetic: DNA methylation in disease states

Common Variants

| Variant | rsID | Effect | Frequency |
|---------|------|--------|-----------|
| P480L | rs28933093 | Mild deficiency | Rare |
| G470A | rs28933094 | Altered activity | Rare |
| 5'UTR variants | Multiple | Altered expression | Common |
| Synonymous variants | Multiple | Generally neutral | Common |

Therapeutic Implications

Antioxidant Therapy

GSS as a therapeutic target:

• GSH precursors: N-acetylcysteine, NAC amide
• GSS activators: Nrf2 agonists (sulforaphane, bardoxolone)
• Gene therapy: AAV-mediated GSS delivery[gss2023]

Drug Development

Current approaches:

• Small molecule GSS activators
• Mitochondria-targeted GSH analogs (mito-GSH)
• Protein-protein interaction inhibitors

Biomarker Potential

GSS activity serves as:

• Biomarker for oxidative stress
• Prognostic indicator in neurodegeneration
• Treatment response monitor

Interaction Network

GSS interacts with:

• GCLC (glutamate-cysteine ligase) — upstream pathway enzyme
• Glutathione reductases (GSR) — regenerates GSH from GSSG
• Glutathione peroxidases (GPX) — uses GSH as cofactor
• Glutathione S-transferases (GSTs) — conjugates GSH
• Gamma-glutamyl transpeptidase (GGT) — degrades GSH
• Nrf2 (NFE2L2) — transcriptional regulator

Biochemical Properties

Enzyme Kinetics

GSS exhibits the following kinetic parameters:

| Parameter | Value | Conditions |
|-----------|-------|------------|
| Km (γ-glutamylcysteine) | 1.2 μM | pH 7.6, 37°C |
| Km (glycine) | 2.8 μM | pH 7.6, 37°C |
| Km (ATP) | 0.4 μM | pH 7.6, 37°C |
| Vmax | 120 μmol/min/mg | Optimal conditions |
| kcat | 85 s⁻¹ | Per subunit |

Regulation Mechanisms

GSS activity is regulated through multiple mechanisms[@gss2021]:

Structural Insights

The crystal structure of GSS reveals[@gss1997]:

• Rossmann-fold architecture typical of ligases
• ATP-binding pocket in C-terminal domain
• Dimerization interface for enzyme assembly
• Active site residues: Asp487, Lys329, Glu432

Glutathione System in Neurodegeneration

Oxidative Stress in AD

The glutathione system is critical in AD pathogenesis[@gss2024]:

Amyloid-β Effects:

• Aβ directly depletes GSH in neurons
• Accelerates ROS production
• Impairs astrocytic GSH release

• Oxidative stress promotes tau aggregation
• NFT formation linked to GSH depletion
• Synaptic GSH loss correlates with cognitive decline

• Microglial activation depletes GSH
• Creates oxidative environment
• Drives progressive neuronal loss

Oxidative Stress in PD

GSS is particularly relevant to PD[@gss2023b][@hj2021]:

Dopaminergic Neuron Vulnerability:

• SNc neurons have inherently low GSH
• Limited antioxidant capacity
• High oxidative demand

• GSH protects against complex I damage
• mtGSH depletion in PD models
• Rotenone/MPTP models show GSH loss

• Oxidative stress accelerates aggregation
• GSH modulates aggregation kinetics
• GSH depletion precedes aggregation

ALS and GSS

Motor neurons are particularly vulnerable to GSH depletion[gss2017]:

• Low GSH in spinal cord
• Impaired antioxidant response
• Excitotoxicity exacerbates depletion
• Therapeutic potential of GSH precursors

Therapeutic Strategies

GSH Precursors

The most direct approach to enhance GSS function:

| Compound | Mechanism | Status |
|----------|-----------|--------|
| N-acetylcysteine (NAC) | Cysteine prodrug | Clinical use |
| NAC amide | Mitochondria-targeted | Phase 2 |
| GSH ethyl ester | Cell-permeable GSH | Preclinical |
| Ribose-cysteine | NADPH generation | Research |

GSS Activators

Direct targeting of GSS:

Nrf2 Agonists:

• Sulforaphane: Upregulates GSS expression
• Bardoxolone: Activates Nrf2 pathway
• Oltipraz: Chemopreventive

• GSS-specific activators in development
• Allosteric modulators
• ATP-binding site ligands

Gene Therapy

Viral delivery of GSS[gss2023]:

• AAV-GSS in preclinical models
• Improved mitochondrial GSH
• Protected dopaminergic neurons
• Translation to clinical use

GSS Deficiency Clinical Features

5-Oxoprolinuria

GSS deficiency causes 5-oxoprolinuria[gss2003]:

| Feature | Pathogenesis |
|---------|--------------|
| 5-oxoproline accumulation | Block in GSH synthesis |
| Metabolic acidosis | Organic acid accumulation |
| Hemolytic anemia | Oxidative stress in RBCs |
| Neurological symptoms | CNS involvement |
| Developmental delay | Progressive |

Genotype-Phenotype Correlations

GSS mutations show variable severity:

| Mutation Type | Severity | Residual Activity |
|--------------|----------|-------------------|
| Missense (P480L) | Mild | 30-40% |
| Nonsense | Severe | <5% |
| Splice site | Variable | 10-60% |
| Deletion | Severe | 0% |

Research Methods

Enzymatic Assays

• GSS activity assay: Continuous spectrophotometric
• GSH/GSSG ratio: HPLC with electrochemical detection
• ATP consumption: Coupled assay

Molecular Techniques

• Western blot: GSS protein levels
• qPCR: GSS mRNA expression
• Immunohistochemistry: Tissue localization
• CRISPR: Gene editing

Model Systems

• Cell culture: Neuronal, astrocytic lines
• iPSC-derived: Patient neurons
• Mouse models: GSS knockout, transgenic
• C. elegans: Oxidative stress models

Population Genetics

Variant Frequencies

GSS polymorphisms in populations[gss2014]:

| rsID | Variant | Frequency (EA) | Function |
|------|---------|----------------|----------|
| rs28933093 | P480L | 0.02 | Mild deficiency |
| rs28933094 | G470A | 0.01 | Altered activity |
| rs3765014 | Promoter | 0.15 | Altered expression |

Disease Associations

• AD: Various GSS variants
• PD: GSS polymorphisms
• ALS: GSS variants
• Autism: GSS associations

Summary

GSS (Glutathione Synthetase) is the second enzyme in the glutathione biosynthesis pathway, catalyzing the ATP-dependent conversion of γ-glutamylcysteine and glycine to form glutathione (GSH). GSH is the most abundant cellular antioxidant and plays critical roles in protecting neurons from oxidative stress, maintaining mitochondrial function, and modulating neuroinflammation.

GSS dysfunction is implicated in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. The enzyme is particularly important in dopaminergic neurons, which have inherently low GSH levels and are highly vulnerable to oxidative damage.

Therapeutic strategies targeting GSS include GSH precursors, Nrf2 activators, and gene therapy approaches. Understanding GSS biology provides opportunities for developing neuroprotective therapies for age-related neurodegenerative disorders.

Mechanistic Pathways in Neurodegeneration

Oxidative Stress Cascade in AD

GSS in Mitochondrial Health

Therapeutic Targeting

| Strategy | Mechanism | Current Status |
|----------|-----------|----------------|
| N-acetylcysteine (NAC) | GSH precursor | Clinical use for various conditions |
| NAC amide | Mitochondria-targeted | Phase 2 trials |
| Sulforaphane | Nrf2 agonist → GSS upregulation | Preclinical/Phase 1 |
| AAV-GSS | Gene therapy delivery | Preclinical |
| GSH analogs (mito-GSH) | Mitochondrial targeting | Research |

See Also

• [Glutathione Metabolism](/mechanisms/glutathione-metabolism)
• [Antioxidant Defense](/mechanisms/antioxidant-defense)
• [Oxidative Stress Pathway](/mechanisms/oxidative-stress-pathway)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Genes Index](/genes-index)

External Links

• [NCBI Gene - GSS](https://www.ncbi.nlm.nih.gov/gene/2937)
• [OMIM - GSS](https://www.omim.org/entry/601002)
• [UniProt - GSS](https://www.uniprot.org/uniprot/P16455)
• [Ensembl - GSS](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100977)

References